Valirx Plc · LSE:VAL
Valirx — Investor Presentation (November 2022)
13 slides from Valirx's investor presentation, November 2022
Slide 1: LSE Investor Presentation introducing Cytolytix
November 2022 LSE Investor Presentation introducing Cytolytix ValiRx @valirxplc www.valirx.com info@valirx.com
Slide 2: Disclaimer
Disclaimer The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the ‘Presentation’) have not been approved by an authorised person withi
Slide 3: ValiRx at a Glance
ValiRx at a Glance £2.5m raised (June 22) 2 therapies Focus on oncology – significantly reduced undergoing out- and women’s health cash burn licensing Evaluation projects Single asset pipeline tCRO strategy subsidiary for triple negative breast cancer 3 Connected Innovation
Slide 4: Team – a Deep Experience of the Sector
Team – a Deep Experience of the Sector Core Strategy Team Dr Suzanne Dilly Mark Treharne Other Board Members: Chief Executive Officer Corporate Development Martin Lampshire (NED) Manager Gerry Desler (CFO) Entrepreneur Innovator network Stella Panu (NED) NEW! Pharmaceutical scientist Investor Relati
Slide 5: Development Pipeline
Development Pipeline Discovery Optimisation Pre-clinical Phase 1 Phase 2 CLX001 Triple Negative Breast Cancer Hokkaido University Under Evaluation Agreement Barcelona University Under Evaluation Agreement VAL301 Endometriosis BC201 Sepsis and Covid-19 complications VAL201 prostate cancer VAL401 lung
Slide 6: ValiRx Provides Solid Start on Pathway to Sales
ValiRx Provides Solid Start on Pathway to Sales AI-driven virtual drug discovery Universities Biotech platform (in-house) Patent filed Mid-size Biotech/SPVs Big Pharma/Specialty Pharma Patent life (years) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Early Discovery Stage of Preclinical Ph 1 Ph
Slide 7: Bridging the Gap Needs Rigorous Preclinical Work
Bridging the Gap Needs Rigorous Preclinical Work Academic research Valley of Death Pharma Partner Chemical Synthesis Stability Physical properties IP Regulatory Drug Absorption TPP Distribution Trial design PoC Toxicology Pharmacokinetics Pharmacodynamics Formulation ValiRx tCRO Only c10% of academi
Slide 8: CLX001 – a novel cancer cell buster
CLX001 – a novel cancer cell buster Indication: • Triple Negative Breast Cancer and other hard to treat cancers Mode of Action: • Creates pores in cancer cell membranes, causing lysis and cell death • Highly specific to cancerous cells, without needing a specific cancer marker Product: • Synthetic p
Slide 9: Triple Negative Breast Cancer (TNBC)
Triple Negative Breast Cancer (TNBC) • Characterised by lack of Estrogen Receptors (ER); Progesterone Receptors (PR) and HER2 Receptors – hence ‘triple negative’ • Breast cancer can be diagnosed as triple negative, or recur as triple negative on relapse after earlier chemotherapies • Difficult to tr
Slide 10: CLX001 – the peptide
CLX001 – the peptide • Kings screened a focussed library of 36 peptides, proposing EEK (now CLX001) as lead candidate • Library varied amino acid in three positions • Synthetic peptide with 15 amino acids, all naturally occurring • Nanoformulation delivers package of peptide molecules to the tumour
Slide 11: Mechanism of Action
Mechanism of Action CLX001 Cell Membrane CLX001 molecules CLX001 attaches and Aqueous pores form through selectively target perforates the cell the membrane causing cancerous cell membrane leakage and eventual cell membranes death 11 Connected Innovation
Slide 12: Status of Development
Status of Development • In vivo assays by Kings showed eradication of tumours in some animals after a ten day treatment schedule, animals remained tumour-free at 200 days • In vitro assays by ValiRx and Kings show activity in ovarian as well as breast cancer in patient derived cells • Toxicology pro
Slide 13: Contacts
Contacts • Suzanne Dilly – Chief Executive Officer • Kevin Cox – Non-Executive Chairman - Suzanne.Dilly@valirx.com - Kevin.Cox@valirx.com • Cathy Tralau-Stewart – Chief Scientific • Mark Treharne – Corporate Development Officer Manager - Cathy.Tralau-Stewart@valirx.com - Mark.Treharne@valirx.com Val